|
CA2307278A1
(en)
*
|
2000-04-28 |
2001-10-28 |
University Of British Columbia |
Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
AU2004257289A1
(en)
*
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
JP4886511B2
(ja)
|
2003-07-30 |
2012-02-29 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
|
|
WO2005077938A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
JP2008508190A
(ja)
*
|
2004-07-19 |
2008-03-21 |
ノボ ノルディスク アクティーゼルスカブ |
肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
|
|
MY145822A
(en)
*
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
AU2005286593A1
(en)
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyridine compounds, process for their preparation and compositions containing them
|
|
DE102005023943A1
(de)
|
2005-05-20 |
2006-11-23 |
Grünenthal GmbH |
Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
AU2006254840B2
(en)
|
2005-06-08 |
2012-08-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
BRPI0714409A2
(pt)
*
|
2006-07-14 |
2013-03-12 |
Novartis Ag |
derivados de pirimidina como inibidores de alk-5
|
|
WO2008057300A2
(en)
*
|
2006-10-27 |
2008-05-15 |
Redpoint Bio Corporation |
Trpvi antagonists and uses thereof
|
|
CA2672893C
(en)
|
2006-12-15 |
2016-02-23 |
Abraxis Bioscience, Inc. |
Triazine derivatives and their therapeutical applications
|
|
AU2008215948A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
|
WO2008121387A1
(en)
*
|
2007-03-30 |
2008-10-09 |
University Of Miami |
Substituted triazine compounds for nerve regeneration
|
|
EP2214486A4
(en)
*
|
2007-10-19 |
2011-03-09 |
Avila Therapeutics Inc |
HETEROARYL COMPOUNDS AND ITS USES
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP2012529517A
(ja)
|
2009-06-09 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
ベンジル置換トリアジン誘導体類及びそれらの治療応用
|
|
JP2012529519A
(ja)
|
2009-06-09 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
スチリル−トリアジン誘導体類及びそれらの治療応用
|
|
KR101457027B1
(ko)
|
2009-06-09 |
2014-10-31 |
캘리포니아 캐피탈 에쿼티, 엘엘씨 |
트리아진 유도체와 이들의 치료적 용도
|
|
ES2390326B1
(es)
*
|
2011-04-05 |
2013-08-14 |
Universidad Miguel Hernández De Elche |
Antagonistas de trpv1 y sus usos.
|
|
EP2802577B1
(en)
|
2012-01-13 |
2017-03-01 |
Bristol-Myers Squibb Company |
Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
US9242976B2
(en)
|
2012-01-13 |
2016-01-26 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
WO2013106612A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
ES2616812T3
(es)
|
2012-11-08 |
2017-06-14 |
Bristol-Myers Squibb Company |
Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
|
|
PE20150953A1
(es)
|
2012-11-08 |
2015-06-20 |
Bristol Myers Squibb Co |
Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
|
|
HUE050761T2
(hu)
|
2014-01-01 |
2021-01-28 |
Medivation Tech Llc |
Vegyületek és alkalmazási eljárások
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
AR105113A1
(es)
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
|
UY36747A
(es)
|
2015-06-24 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
|
|
US10618903B2
(en)
|
2015-06-24 |
2020-04-14 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
MY200228A
(en)
|
2017-05-11 |
2023-12-15 |
Bristol Myers Squibb Co |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
|
WO2019119206A1
(en)
*
|
2017-12-18 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Purine inhibitors of human phosphatidylinositol 3-kinase delta
|
|
CN108863949B
(zh)
*
|
2018-07-09 |
2021-01-15 |
湖南博隽生物医药有限公司 |
一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法
|
|
WO2021011724A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
WO2021011727A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
CN114174279B
(zh)
|
2019-08-06 |
2024-07-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的双环杂环化合物
|
|
US12570659B2
(en)
|
2019-08-13 |
2026-03-10 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl compounds useful as IRAK4 inhibitors
|
|
CN113134005B
(zh)
*
|
2020-01-16 |
2022-09-23 |
中国药科大学 |
Trpv1通道靶向小分子的应用
|
|
CN115335380B
(zh)
|
2020-02-03 |
2024-08-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的三环杂芳基化合物
|
|
US12391702B2
(en)
|
2020-02-03 |
2025-08-19 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
|
|
DE102022104759A1
(de)
|
2022-02-28 |
2023-08-31 |
SCi Kontor GmbH |
Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
|